As a result, Roche TIGIT monoclonal antibody tiragolumab has been recognized by FDA as a breakthrough therapy designation and combined with PD-L1 monoclonal antibody atezolizumab for the first-line treatment of metastatic non-small cell lung cancer with high expression of PD-L1 and non-EGFR nor ALK mutation patients. Here, ALK is linked to non-small cell lung carcinoma.